MGF E-domain
Also known as Mechano Growth Factor · IGF-1Ec splice variant
IGF-1 splice variant peptide studied preclinically for muscle repair signaling.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
No Human Data
No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.
Evidence visual
MGF E-domain evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
extreme
Regulatory
not approved
WADA
S2
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
MGF (Mechano Growth Factor) E-domain relates to IGF-1 splice variants and muscle repair signaling. Preclinical localized delivery studies exist. The mechanism involves IGF-1 receptor signaling with differences across variants. WADA lists MGF under growth factor modulators.
Decision path
Where MGF E-domain fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether MGF E-domain belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
IGF-1 splice variant involved in muscle repair signaling; IGF-1 receptor signaling with variant-specific differences.
subcutaneous
Preclinical: localized delivery studies. No established human dosing.
Muscle repair signaling in preclinical models.
Preclinical outcomes vary by model.
No human data.
Limited data; growth-factor class concerns apply.
Unknown.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for MGF E-domain.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.